| 1 |
Ma K, Chen S, Chen X, Yang C, Yang J. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. World Neurosurg 2022;165:e650-63. [PMID: 35779750 DOI: 10.1016/j.wneu.2022.06.124] [Reference Citation Analysis]
|
| 2 |
Ma K, Chen S, Chen X, Zhao X, Yang J. CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance. J Mol Neurosci 2022. [PMID: 36006582 DOI: 10.1007/s12031-022-02060-4] [Reference Citation Analysis]
|
| 3 |
Ma K, Chen X, Zhao X, Chen S, Yang J. PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis. Heliyon 2022;8:e10298. [PMID: 36033326 DOI: 10.1016/j.heliyon.2022.e10298] [Reference Citation Analysis]
|
| 4 |
Sansone G, Vivori N, Vivori C, Di Stefano AL, Picca A. Basic premises: searching for new targets and strategies in diffuse gliomas. Clin Transl Imaging. [DOI: 10.1007/s40336-022-00507-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Ramlee S, Hulse D, Bernatowicz K, Pérez-lópez R, Sala E, Aloj L. Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study. Cancers 2022;14:3656. [DOI: 10.3390/cancers14153656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Xie Q, Huang X, Huang W, Liu F. PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas. Front Oncol 2022;12:860640. [PMID: 35756621 DOI: 10.3389/fonc.2022.860640] [Reference Citation Analysis]
|
| 7 |
Salvalaggio A, Silvestri E, Sansone G, Pinton L, Magri S, Briani C, Anglani M, Lombardi G, Zagonel V, Della Puppa A, Mandruzzato S, Corbetta M, Bertoldo A. Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma. Front Oncol 2022;12:823812. [PMID: 35392230 DOI: 10.3389/fonc.2022.823812] [Reference Citation Analysis]
|
| 8 |
Ma K, Chen X, Liu W, Chen S, Yang C, Yang J. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. Sci Rep 2022;12:4295. [PMID: 35277559 DOI: 10.1038/s41598-022-08346-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Zhou Q, Xue C, Ke X, Zhou J. Treatment Response and Prognosis Evaluation in High-Grade Glioma: An Imaging Review Based on MRI. J Magn Reson Imaging 2022. [PMID: 35129845 DOI: 10.1002/jmri.28103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 10 |
Kim AR, Choi SJ, Park J, Kwon M, Chowdhury T, Yu HJ, Kim S, Kang H, Kim KM, Park SH, Park CK, Shin EC. Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma. Oncoimmunology 2022;11:2026019. [PMID: 35036078 DOI: 10.1080/2162402X.2022.2026019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Choi KS. Deep Learning Applications in Perfusion MRI: Recent Advances and Current Challenges. Investig Magn Reson Imaging 2022;26:246. [DOI: 10.13104/imri.2022.26.4.246] [Reference Citation Analysis]
|
| 12 |
Fathi Kazerooni A, Bagley SJ, Akbari H, Saxena S, Bagheri S, Guo J, Chawla S, Nabavizadeh A, Mohan S, Bakas S, Davatzikos C, Nasrallah MP. Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine. Cancers (Basel) 2021;13:5921. [PMID: 34885031 DOI: 10.3390/cancers13235921] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 13 |
Raghavan JV, Ganesh RA, Sonpatki P, Naik D, John AE, Arunachalam P, Shah D, P S H, Lakshmikantha A, Pillai S, Chandrachari KP, Mariswamappa K, Lale S, Shah N, Jhunjhunwala S. Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin. Oncoimmunology 2021;10:1957215. [PMID: 34377594 DOI: 10.1080/2162402X.2021.1957215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
